65,437 trials
Necrotizing Soft Tissue Infections · Necrotizing Fasciitis · Fournier's Gangrene
Primary: Number of Patients Achieving Necrotizing Infections Clinical Composite Endpoint (NICCE) — 69; 59; 67; 50 Participants — p=0.135
Benign Prostatic Hyperplasia · Lower Urinary Track Symptoms
Primary: American Urologic Association Symptom Score (AUASS) — 18.66; 14.16 score on a scale
Post-operative Pain Control
Primary: Post-operative Average Pain Score — 2.82; 3.58 units on a scale
Vehicular Environment
Primary: Collect Preliminary Data on In-vehicle Excess Particulate Matter (PM) Exposure
Chronic Hepatitis C Infection
Primary: Part 1: Maximum Plasma Concentration (Cmax) of Ombitasvir (OBV) — 99.6; 116; 83.7 ng/mL
Traumatic Brain Injury
Primary: Functional Independence Measure Scores — 88.11; 89.79; 120.57; 119.67 units on a scale
Normal Physiology
Primary: Difference Between Arms in the Change of Pressure Intensity From Baseline to After Loss of A-beta Sensation — -25.0 Units on a scale
Melanoma
Primary: Intracranial Clinical Benefit Rate (CBR) — 57.4; 16.7 Percentage of Participants
Opioid Sensitivity · Individual Difference · Abuse Opioids
Primary: Self-report Visual Analog Ratings of HIGH — 7.2; 6.6; 4.5; 5.6 score on a scale — p=0.567
G6PD Deficiency
Primary: Sensitivity of SD Biosensor STANDARD G6PD Test for Identifying G6PD Deficient Individuals — 100.0; 100.0 percentage of participants
STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER
Primary: 2-year Overall Survival (Phase II) — 66.5; 55.5 percentage of participants
Antibotics in Cementless Knees
Primary: Concentration of Antibiotics in Cementless Knees Post op — 1702.5; 582.5; 56.1; 1943 micrograms per milliliter
Cesarean Section Complications · Wound Breakdown · Wound Infection
Primary: Satisfaction and QoL Questionnaire — 49; 52 Score
Hepatic Malignancies
Primary: Reproducibility Coefficient (RDC) Between the Two Imaging Modalities in Liver Tumor Tissues — 16.9 percent difference
Acute Repetitive Seizures
Primary: Cmax of Diazepam After Single Intranasal Doses of NRL-1 (Diazepam Nasal Spray) Administered to Epilepsy Subjects During the Ictal or Peri-ictal Period — 135; 153 ng/mL